# EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT

> **NCT07695311** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Rabi Hanna** · enrollment: 24 (estimated)

## Conditions studied

- Ewing Sarcoma
- Desmoplastic Small Round Cell Tumor

## Interventions

- **DRUG:** EWSR1 immunotherapy
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07695311
- **Lead sponsor:** Rabi Hanna
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-10
- **Final completion:** 2030-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695311, "EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*